View Older Stories

Oct 20, 2025 02:52PM JPMorgan Upgrades Replimune Group (REPL) to Neutral

Oct 20, 2025 02:27PM Replimune (REPL) call put ratio 1.2 calls to 1 put as share price up 105%

Oct 20, 2025 10:20AM Leerink Partners Upgrades Replimune Group (REPL) to Outperform

Oct 20, 2025 10:02AM Increasing unusual put option volume: REPL LBRT ARCT CRML BYND ABAT BITF EXEL

Oct 20, 2025 08:59AM Wedbush Upgrades Replimune Group (REPL) to Outperform

Oct 20, 2025 07:02AM FDA accepts Replimune BLA resubmission for RP1 melanoma treatment

Sep 19, 2025 06:51AM H.C. Wainwright Reiterates Neutral Rating on Replimune Group (REPL)

Sep 19, 2025 02:13AM JPMorgan Downgrades Replimune Group (REPL) to Underweight

Sep 18, 2025 09:15AM Replimune meets with FDA on melanoma treatment application

Sep 9, 2025 06:50AM H.C. Wainwright Reiterates Neutral Rating on Replimune Group (REPL)

Sep 2, 2025 08:02AM Replimune schedules FDA meeting on melanoma treatment application

Aug 11, 2025 05:30AM Replimune Group (REPL) PT Lowered to $8 at Jefferies

Jul 31, 2025 02:12PM Important Notice to Long-term Shareholders of Replimune Group, Inc. (REPL): Grabar Law Office Investigates Claims on Your Behalf

Jul 31, 2025 05:01AM Increasing unusual option volume: SMCY REPL ROIV PARA CRDF OPEN CWH PAGP LC CP

Jul 30, 2025 01:43PM Cantor Fitzgerald Upgrades Replimune Group (REPL) to Overweight

Jul 30, 2025 10:03AM Increasing unusual option volume: REPL CP PGEN CRDF LC INDA NEO TTI JBS HOG TER

Jul 29, 2025 03:19PM Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman

Jul 23, 2025 06:06AM H.C. Wainwright Downgrades Replimune Group (REPL) to Neutral

Jul 23, 2025 06:00AM Increasing unusual put option volume: OPEN REPL NOK AAOI GRPO ATYR HPP ETHE

Jul 23, 2025 12:29AM BMO Capital Downgrades Replimune Group (REPL) to Underperform

Jul 22, 2025 04:31PM Barclays Downgrades Replimune Group (REPL) to Equalweight

Jul 22, 2025 01:19PM Leerink Partners Downgrades Replimune Group (REPL) to Market Perform

Jul 22, 2025 12:31PM Leerink Partners Reiterates Outperform Rating on Replimune Group (REPL), PT $21, 'Estimates Under Review'

Jul 22, 2025 11:18AM Replimune Group (REPL) PT Lowered to $6 at Jefferies, Buy rating kept, 'see the reasonable case as accelerated approval based on interim results'

Jul 22, 2025 10:30AM Increasing unusual option volume: REPL OPEN PGEN NXDR UPXI UGL AAOI

Jul 22, 2025 09:50AM Wedbush Downgrades Replimune Group (REPL) to Neutral

Jul 22, 2025 09:15AM Replimune Group Stock Drops More Than 75% on News of FDA Complete Response Letter - Kehoe Law Firm, P.C. Investigating Securities Claims on Behalf of Investors - REPL

Jul 22, 2025 09:09AM Cantor Fitzgerald Downgrades Replimune Group (REPL) to Neutral, Only Firm Thus Far Not Buy/Overweight Rated

Jul 22, 2025 08:53AM BMO Capital Reiterates Outperform Rating on Replimune Group (REPL), PT $27, 'we see a long road ahead'

Jul 22, 2025 08:52AM Mizuho Desk Comments on Replimune (REPL)

Jul 22, 2025 08:50AM Barclays Reiterates Overweight Rating on Replimune Group (REPL), PT $17, 'We see this as a clear positive for Iovance's Amtagvi'

Jul 22, 2025 07:03AM Replimune receives FDA rejection letter for melanoma treatment

Jul 15, 2025 02:47PM Replimune (REPL) 11,800 contracts of July 12.50 calls trade, share price up 6.4%

Jul 7, 2025 09:38AM Increasing unusual call option volume: BTBT ACLS CNC SHLS REPL

Jul 7, 2025 06:36AM H.C. Wainwright Reiterates Buy Rating on Replimune Group (REPL)

Jun 25, 2025 07:04AM Cantor Fitzgerald Reiterates Overweight Rating on Replimune Group (REPL)

Jun 20, 2025 06:09AM Cantor Fitzgerald Starts Replimune Group (REPL) at Overweight

Jun 3, 2025 10:07AM JPMorgan Reiterates Overweight Rating on Replimune Group (REPL)

Jun 2, 2025 06:43AM Replimune Group (REPL) PT Raised at Piper Sandler; 'Raising Numbers After Multiple Recent Updates'

May 22, 2025 07:17AM Replimune Group, Inc. (REPL) Misses Q4 EPS by 235c

Feb 13, 2025 06:48AM Replimune Group (REPL) PT Raised to $22 at H.C. Wainwright

Jan 21, 2025 11:00AM Replimune Group (REPL) PT Raised to $27 at BMO Capital

Jan 21, 2025 10:32AM Barclays Reiterates Overweight Rating on Replimune Group (REPL)

Jan 21, 2025 08:05AM Replimune (REPL) Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

Dec 3, 2024 03:59PM Replimune Group (REPL) PT Raised to $19 at Jefferies

Nov 26, 2024 06:05AM Replimune (REPL) Prices Upsized 6.92M Share Offering at $13/sh

Nov 25, 2024 07:10AM Replimune (REPL) Announces $125M Proposed Public Offering

Nov 22, 2024 09:08AM Replimune Group (REPL) PT Raised to $18 at BMO Capital

Nov 21, 2024 04:42PM After-hours movers: Intuit, NetApp, Ross Stores, GAP

Nov 21, 2024 04:06PM Replimune (REPL) Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

View Older Stories